1. A 58-year-old man with a hospital-acquired gram-negative pneumonia is being started on imipenem. The formulary preparation available is imipenem-cilastatin. A medical student asks why cilastatin is included in this formulation. Which of the following best explains the pharmacological rationale for combining cilastatin with imipenem?
A) Cilastatin inhibits bacterial beta-lactamases, preventing enzymatic inactivation of imipenem in the periplasm
B) Cilastatin inhibits renal dehydropeptidase I, preventing hydrolytic inactivation of imipenem in the proximal tubule
C) Cilastatin blocks renal organic anion transporters, prolonging the serum half-life of imipenem by reducing tubular secretion
D) Cilastatin chelates divalent cations in the renal tubule, stabilizing the imipenem beta-lactam ring against spontaneous hydrolysis
E) Cilastatin competitively inhibits the penicillin-binding proteins responsible for imipenem clearance from renal tissue
ANSWER: B
Rationale:
Imipenem undergoes hydrolysis by dehydropeptidase I (DHP-I), a zinc-dependent metalloprotease located on the brush border of proximal renal tubular cells. Without inhibition of DHP-I, a substantial fraction of administered imipenem is inactivated before reaching its urinary target, and potentially nephrotoxic metabolites are generated. Cilastatin is a specific, reversible inhibitor of DHP-I that blocks this hydrolytic pathway, preserving imipenem urinary concentrations and eliminating the toxic tubular metabolites.
Option A: Option A is incorrect; cilastatin has no beta-lactamase inhibitory activity and does not protect imipenem from enzymatic resistance mechanisms in bacteria.
Option C: Option C is incorrect; cilastatin does not act on organic anion transporters, and prolongation of serum half-life is not its primary function.
Option D: Option D is incorrect; the mechanism of DHP-I inhibition is enzymatic, not cation chelation, and the beta-lactam ring instability in this context is enzymatic rather than chemical.
Option E: Option E is incorrect; penicillin-binding proteins (PBPs) are bacterial transpeptidases that are imipenem's target, not enzymes responsible for its renal clearance.
2. A pharmacology lecture discusses why carbapenems resist hydrolysis by most beta-lactamases despite being beta-lactam antibiotics. The instructor points to a specific structural feature that distinguishes carbapenems from penicillins and cephalosporins. Which structural feature of carbapenems is primarily responsible for their stability against hydrolysis by extended-spectrum beta-lactamases (ESBLs) and most serine beta-lactamases?
A) The presence of a sulfur atom at position 1 of the bicyclic ring system, which sterically occludes the beta-lactamase active site
B) Replacement of the nitrogen at position 1 with a carbon atom, creating a carbapenem ring that fits poorly into beta-lactamase binding pockets
C) The trans-configuration of the C-5 and C-6 substituents, which positions the carbonyl carbon away from the beta-lactamase serine residue
D) A 1-beta-methyl (hydroxyethyl) side chain at C-6 in a trans configuration that sterically hinders access of beta-lactamase to the beta-lactam carbonyl
E) An extended C-2 side chain that forms a covalent adduct with the conserved lysine residue in class A beta-lactamase active sites
ANSWER: D
Rationale:
The defining structural feature responsible for carbapenem beta-lactamase stability is the 1-beta-hydroxyethyl (trans-1-hydroxyethyl) substituent at C-6 of the bicyclic ring. This bulky trans side chain creates steric hindrance that impairs binding of most serine beta-lactamases (class A, class C, and class D) to the carbonyl carbon of the beta-lactam ring, preventing productive hydrolysis. This same feature distinguishes carbapenems from penicillins (which have an acyl side chain at C-6 with no equivalent steric protection) and from cephalosporins. Class B metallo-beta-lactamases (NDM [New Delhi metallo-beta-lactamase], VIM, IMP) use a zinc-mediated hydrolytic mechanism that bypasses this steric barrier, explaining why carbapenems are hydrolyzed by class B enzymes despite the hydroxyethyl group.
Option A: Option A is incorrect; carbapenems do have a carbon (not sulfur) at position 1, and this carbon substitution is a structural identity feature but is not the primary mechanism of beta-lactamase resistance.
Option B: Option B is incorrect in its framing; while the C-1 carbon is a distinguishing feature, beta-lactamase resistance derives from the C-6 substituent, not from poor ring fit attributable to the 1-carbon.
Option C: Option C is incorrect; the trans configuration at C-5/C-6 is real but does not describe the dominant mechanism of beta-lactamase resistance, which centers on the hydroxyethyl group at C-6.
Option E: Option E is incorrect; carbapenems do not form covalent adducts with beta-lactamase lysine residues; their resistance is steric, not mechanism-based inhibition of beta-lactamase.
3. A 44-year-old woman is admitted with complicated intra-abdominal infection acquired outside the hospital. Blood cultures are drawn and empiric therapy is being selected. The infectious disease consultant recommends ertapenem rather than meropenem, citing ertapenem's once-daily dosing advantage. A resident asks which clinically important pathogens ertapenem does NOT reliably cover, making it inappropriate for certain hospital-acquired infections. Which of the following organisms is NOT reliably covered by ertapenem?
A) Pseudomonas aeruginosa
B) Escherichia coli producing an extended-spectrum beta-lactamase (ESBL)
C) Klebsiella pneumoniae producing AmpC beta-lactamase
D) Bacteroides fragilis
E) Enterobacter cloacae with inducible AmpC
ANSWER: A
Rationale:
Ertapenem has a critical coverage gap compared to other carbapenems: it lacks reliable activity against Pseudomonas aeruginosa and Acinetobacter baumannii. This gap results from ertapenem's poor affinity for the outer membrane porins (OprD) used by carbapenems to enter Pseudomonas, combined with rapid efflux by the MexAB-OprM pump. Clinically, this means ertapenem is appropriate for community-acquired or healthcare-associated infections with enteric gram-negatives and anaerobes, but should never be used empirically when Pseudomonas is a possible pathogen (e.g., hospital-acquired pneumonia, ventilator-associated infections, infections in neutropenic or severely immunocompromised patients).
Option B: Option B is incorrect; ertapenem retains excellent activity against ESBL-producing E. coli and Klebsiella, and is guideline-supported for definitive therapy of ESBL-E infections when source control is achieved.
Option C: Option C is incorrect; ertapenem is active against AmpC-producing Enterobacteriaceae, although high-level AmpC combined with porin loss can reduce susceptibility.
Option D: Option D is incorrect; ertapenem covers Bacteroides fragilis and other anaerobes, which is one reason it is well-suited for intra-abdominal infections.
Option E: Option E is incorrect; ertapenem retains activity against Enterobacter cloacae with inducible AmpC in most clinical scenarios, though isolates with combined AmpC overexpression and porin loss may show reduced susceptibility.
4. A 67-year-old man with a documented severe IgE-mediated penicillin allergy (anaphylaxis to ampicillin three years ago) develops a gram-negative bacteremic urinary tract infection with a susceptibility pattern that would favor a beta-lactam antibiotic. The infectious disease team considers aztreonam. Which of the following best describes the cross-reactivity risk between aztreonam and penicillins in this clinical setting?
A) Aztreonam carries high cross-reactivity with penicillins because both share the bicyclic beta-lactam-thiazolidine ring system recognized by IgE antibodies
B) Aztreonam is contraindicated in patients with penicillin allergy because beta-lactam ring IgE antibodies cross-react with all members of the class equally
C) Aztreonam has negligible cross-reactivity with penicillins because it is a monocyclic beta-lactam (monobactam) without the bicyclic ring structure shared by penicillins, cephalosporins, and carbapenems
D) Aztreonam is safe in all penicillin-allergic patients because the monobactam nucleus does not contain a beta-lactam ring and therefore cannot be recognized by anti-penicillin IgE
E) Aztreonam shares the same R1 side chain as ampicillin, making cross-reactivity likely in patients with ampicillin-specific IgE but not in patients with allergy to other penicillins
ANSWER: C
Rationale:
Aztreonam is a monobactam — the only clinically used member of the monocyclic beta-lactam class. Unlike penicillins (bicyclic beta-lactam-thiazolidine), cephalosporins (bicyclic beta-lactam-dihydrothiazine), and carbapenems (bicyclic beta-lactam-pyroline), aztreonam contains a single beta-lactam ring without a fused second ring. Immunologically, penicillin allergy is mediated primarily against epitopes on the bicyclic ring degradation products (penicilloyl determinant) or the fused ring system, which aztreonam lacks entirely. Clinical and pharmacological data consistently demonstrate negligible cross-reactivity between aztreonam and penicillins, and aztreonam is considered safe to use in penicillin-allergic patients.
Option A: Option A is incorrect; aztreonam does not share the bicyclic beta-lactam-thiazolidine ring of penicillins, so the epitopes driving penicillin IgE responses are not present in aztreonam.
Option B: Option B is incorrect; this overstates cross-reactivity risk and contradicts well-established clinical guidance supporting aztreonam use in penicillin-allergic patients.
Option D: Option D is incorrect on a factual point: aztreonam does contain a beta-lactam ring — it is specifically the monocyclic (non-fused) nature of that ring that eliminates cross-reactivity, not the absence of a beta-lactam ring.
Option E: Option E is incorrect in its implication; while aztreonam shares a similar R1 aminothiazole side chain with ceftazidime (not with ampicillin), the clinically meaningful cross-reactivity issue for this patient involves the bicyclic ring system, not R1 side chains.
5. A 72-year-old woman is in the ICU with gram-negative meningitis following neurosurgical instrumentation. The isolate is susceptible to both imipenem and meropenem. The neurology consultant advises choosing meropenem over imipenem for this patient. Which pharmacological property best justifies this preference in the setting of CNS infection?
A) Meropenem achieves substantially higher CSF concentrations than imipenem due to its lower protein binding and greater lipid solubility
B) Meropenem has a broader spectrum against gram-negative bacilli and covers more PBP subtypes in CNS pathogens than imipenem
C) Meropenem does not require co-administration with cilastatin, reducing the number of infused agents and the risk of renal tubular toxicity in a critically ill patient
D) Meropenem has a longer half-life than imipenem, allowing extended-infusion dosing that maintains higher CSF drug levels throughout the dosing interval
E) Meropenem carries a significantly lower risk of seizures than imipenem, making it the preferred carbapenem when CNS pathology or lowered seizure threshold is present
ANSWER: E
Rationale:
Imipenem is associated with a clinically meaningful risk of seizures, particularly at high doses or in patients with CNS pathology, renal impairment, or pre-existing seizure disorders. The mechanism involves imipenem's interaction with GABA-A (gamma-aminobutyric acid type A) receptors in a manner that reduces inhibitory tone. Meropenem has substantially lower intrinsic seizurogenic potential, attributed to structural differences (specifically the C-1 beta-methyl group on meropenem's ring) that reduce GABA-A antagonism. In CNS infections — where the blood-brain barrier is disrupted, drug CNS exposure is increased, and patients may already have elevated seizure risk from the infection itself — meropenem is the standard carbapenem of choice.
Option A: Option A is incorrect; CSF penetration differences between imipenem and meropenem are not the primary reason for preference, and meropenem does not have dramatically superior CSF pharmacokinetics.
Option B: Option B is incorrect; the spectrum of activity against gram-negative meningitis pathogens is broadly similar between the two agents and is not the basis for the preference.
Option C: Option C is incorrect; while meropenem does not require cilastatin, this is not the reason it is preferred in CNS infections, and cilastatin does not contribute meaningfully to CNS risk.
Option D: Option D is incorrect; imipenem and meropenem have similar half-lives (approximately 1 hour), and half-life is not the pharmacological basis for the CNS preference.
6. A 55-year-old man in the ICU is found to have bacteremia with a Klebsiella pneumoniae isolate that produces NDM (New Delhi metallo-beta-lactamase), a class B metallo-beta-lactamase. The isolate is resistant to all carbapenems, ceftazidime-avibactam, and meropenem-vaborbactam. The infectious disease consultant proposes aztreonam-avibactam. Which pharmacological property of aztreonam forms the scientific rationale for its use in this combination against NDM-producing organisms?
A) Aztreonam is a substrate for NDM but is hydrolyzed far more slowly than carbapenems, allowing sufficient time-dependent killing before inactivation
B) Aztreonam is intrinsically stable to hydrolysis by class B metallo-beta-lactamases including NDM, so it retains activity against NDM-producing organisms when co-produced serine beta-lactamases are inhibited by avibactam
C) Aztreonam binds irreversibly to NDM's zinc cofactors, inactivating the enzyme and restoring carbapenem activity in the same organism simultaneously
D) Aztreonam is imported into NDM-producing organisms via a siderophore uptake pathway that bypasses the outer membrane porin loss responsible for carbapenem resistance
E) Aztreonam inhibits NDM gene transcription by binding to the MBL regulatory promoter region, preventing new NDM enzyme synthesis during treatment
ANSWER: B
Rationale:
Aztreonam's intrinsic resistance to class B metallo-beta-lactamases (including NDM, VIM, and IMP) is a fundamental pharmacological property of the monobactam class, attributed to the monocyclic ring structure that is a poor substrate for the zinc-dependent hydrolytic mechanism of class B enzymes. NDM-producing organisms, however, almost invariably co-produce serine beta-lactamases (ESBLs, AmpC, or KPC) on the same resistance plasmid; these serine enzymes readily hydrolyze aztreonam, negating its intrinsic NDM stability. Avibactam inhibits serine beta-lactamases (class A including KPC, class C AmpC, and class D OXA-48) but does not inhibit class B metallo-beta-lactamases. The aztreonam-avibactam combination exploits this division: avibactam protects aztreonam from co-produced serine beta-lactamases, while aztreonam's intrinsic NDM stability handles the metallo-enzyme.
Option A: Option A is incorrect; aztreonam is not merely a slow NDM substrate — it is genuinely resistant to NDM hydrolysis, not just more slowly hydrolyzed.
Option C: Option C is incorrect; aztreonam does not bind to or inactivate NDM's zinc cofactors and does not restore carbapenem activity.
Option D: Option D is incorrect; aztreonam does not use a siderophore uptake pathway; that mechanism belongs to cefiderocol.
Option E: Option E is incorrect; aztreonam has no mechanism involving inhibition of NDM gene transcription.
7. An infectious disease pharmacist is explaining why ceftazidime-avibactam is effective against KPC (Klebsiella pneumoniae carbapenemase)-producing organisms but not against NDM-producing organisms. The explanation centers on the biochemical mechanism of avibactam. Which of the following correctly describes why avibactam inhibits KPC but not NDM?
A) Avibactam is a competitive inhibitor of metallo-enzymes; KPC contains zinc at its active site while NDM uses a serine residue, making KPC selectively susceptible
B) Avibactam covalently modifies the outer membrane porin used by KPC-producing organisms to import carbapenem antibiotics, restoring drug penetration
C) KPC is a serine beta-lactamase (class A) that uses a serine residue for hydrolysis; avibactam forms a covalent but reversible bond with this serine, inhibiting the enzyme, while NDM is a zinc-dependent (class B) metallo-beta-lactamase that avibactam cannot inhibit
D) KPC produces a conformational change in the imipenem ring that avibactam prevents by binding imipenem directly, while NDM hydrolyzes meropenem via a pathway avibactam cannot block
E) Avibactam selectively inhibits class A enzymes by chelating their calcium cofactors, while NDM's magnesium-dependent active site is unaffected by calcium chelation
ANSWER: C
Rationale:
Beta-lactamases are classified by their hydrolytic mechanism. Class A (including KPC, TEM, SHV, CTX-M), class C (AmpC), and class D (OXA-type) enzymes are serine beta-lactamases: they use a catalytic serine residue in a covalent acyl-enzyme intermediate mechanism to hydrolyze the beta-lactam ring. Class B enzymes (NDM, VIM, IMP) are metallo-beta-lactamases that use one or two zinc ions to activate a water molecule for direct hydrolytic attack on the beta-lactam. Avibactam is a diazabicyclooctane (DBO) non-beta-lactam inhibitor that forms a covalent, slowly reversible carbamylation with the catalytic serine of class A, C, and some class D serine beta-lactamases; it has no mechanism of action against the zinc-dependent active site of class B metallo-beta-lactamases. Therefore, avibactam inhibits KPC (class A serine carbapenemase) effectively but cannot inhibit NDM (class B zinc metalloenzyme).
Option A: Option A is incorrect; the active site assignments are reversed — KPC uses serine, not zinc, and NDM uses zinc, not serine.
Option B: Option B is incorrect; avibactam acts on the beta-lactamase enzyme directly, not on outer membrane porins.
Option D: Option D is incorrect; avibactam acts on the beta-lactamase enzyme, not on the antibiotic molecule itself.
Option E: Option E is incorrect; avibactam does not function through calcium chelation and class A beta-lactamases do not have calcium cofactors.
8. A 68-year-old man with chronic kidney disease (CrCl 28 mL/min) and a history of a single unprovoked seizure two years ago is started on imipenem-cilastatin for a complicated intra-abdominal infection. On day 3 of therapy, he develops a generalized tonic-clonic seizure. Which of the following best describes the pharmacological mechanism responsible for this adverse event?
A) Imipenem antagonizes GABA-A (gamma-aminobutyric acid type A) receptors in the CNS, reducing inhibitory neurotransmission and lowering the seizure threshold; this risk is amplified in renal impairment due to drug accumulation
B) Cilastatin inhibits renal glucuronidation of imipenem's active seizurogenic metabolite, leading to accumulation of the toxic compound in brain tissue
C) Imipenem blocks voltage-gated sodium channels in a use-dependent manner, paradoxically increasing neuronal excitability at high plasma concentrations
D) Cilastatin crosses the blood-brain barrier and directly stimulates glutamate NMDA (N-methyl-D-aspartate) receptors, producing excitotoxic seizure activity
E) Imipenem chelates synaptic calcium ions, disrupting presynaptic inhibitory interneuron firing and producing a net excitatory state in cortical circuits
ANSWER: A
Rationale:
Imipenem is the carbapenem with the highest recognized seizure risk among the class. The mechanism involves GABA-A receptor antagonism: imipenem (and its open-ring hydrolysis products) interact with the picrotoxin-binding site within the GABA-A chloride channel, reducing chloride influx in response to GABA and thereby diminishing inhibitory neurotransmission. The net effect is lowering of the seizure threshold. Risk factors for imipenem-associated seizures include pre-existing CNS disease, prior seizure history, high doses, and renal impairment — because imipenem is renally eliminated, reduced renal function leads to drug accumulation and higher CNS exposure. This patient has three compounding risk factors: renal impairment, prior seizure history, and an intrinsically high-risk drug. Meropenem and ertapenem carry substantially lower seizurogenic potential than imipenem.
Option B: Option B is incorrect; cilastatin inhibits DHP-I (dehydropeptidase I) in the renal tubule and does not affect glucuronidation; imipenem's seizure risk is related to the parent compound and its ring-opened products, not a glucuronide metabolite.
Option C: Option C is incorrect; imipenem does not block voltage-gated sodium channels; its CNS mechanism is GABAergic inhibition.
Option D: Option D is incorrect; cilastatin does not cross the blood-brain barrier in meaningful concentrations and has no glutamate receptor activity.
Option E: Option E is incorrect; calcium chelation is not a recognized mechanism of imipenem neurotoxicity.
9. A hospitalist is planning outpatient parenteral antibiotic therapy (OPAT) for a 52-year-old woman with a complicated urinary tract infection caused by an ESBL-producing Klebsiella pneumoniae. The isolate is susceptible to ertapenem. The hospitalist notes that ertapenem is particularly well-suited for OPAT use compared to other carbapenems. Which pharmacokinetic property of ertapenem most directly enables once-daily outpatient dosing?
A) Ertapenem undergoes minimal renal elimination, reducing the need for dose frequency adjustments and allowing simplified outpatient administration schedules
B) Ertapenem is available in an oral prodrug formulation that achieves adequate bioavailability for outpatient use without intravenous access
C) Ertapenem has a broader post-antibiotic effect (PAE) than meropenem or imipenem against gram-negative organisms, allowing longer between-dose intervals regardless of pharmacokinetic parameters
D) Ertapenem has a substantially longer serum half-life (approximately 4 hours) than imipenem or meropenem (approximately 1 hour each), allowing once-daily IV or IM dosing that maintains adequate time above MIC throughout the 24-hour interval
E) Ertapenem saturates all five penicillin-binding protein (PBP) subtypes simultaneously at standard doses, achieving instantaneous bactericidal killing that does not depend on sustained drug exposure
ANSWER: D
Rationale:
Ertapenem's half-life of approximately 4 hours is substantially longer than those of imipenem and meropenem (each approximately 1 hour), and is the direct pharmacokinetic basis for once-daily dosing. Like all beta-lactams, carbapenems exhibit time-dependent bactericidal activity: efficacy correlates with the percentage of the dosing interval during which free drug concentrations remain above the MIC (minimum inhibitory concentration) of the pathogen. Ertapenem's extended half-life, combined with its high protein binding (approximately 95%), results in a prolonged free-drug exposure profile that sustains adequate time above MIC over a 24-hour interval at the standard 1 g once-daily dose. Imipenem and meropenem's short half-lives necessitate every-6- to every-8-hour dosing to maintain adequate time above MIC.
Option A: Option A is incorrect; ertapenem is primarily renally eliminated, and dose adjustment is required in significant renal impairment — its OPAT advantage is half-life, not elimination route.
Option B: Option B is incorrect; ertapenem has no oral formulation; it is administered intravenously or intramuscularly.
Option C: Option C is incorrect; while beta-lactams do have modest post-antibiotic effects against some gram-negatives, this is not the pharmacokinetic basis for ertapenem's once-daily dosing advantage.
Option E: Option E is incorrect; beta-lactams are time-dependent, not concentration-dependent, and instantaneous saturating killing is not the pharmacological model for this class.
10. A 61-year-old woman with a severe penicillin allergy (prior anaphylaxis) develops urosepsis. Blood cultures grow an Escherichia coli isolate that is reported as susceptible to aztreonam by the automated susceptibility system. The isolate is known to produce an ESBL (extended-spectrum beta-lactamase). The infectious disease consultant advises against relying on aztreonam monotherapy despite the susceptibility report. Which of the following best explains this recommendation?
A) Aztreonam monotherapy is avoided in ESBL-producing organisms because aztreonam binds PBP3 only weakly in ESBL-producing strains, reducing its bactericidal activity regardless of susceptibility testing results
B) Aztreonam should be avoided because ESBLs upregulate efflux pump expression, causing aztreonam to be actively exported from the periplasm before it can bind its target PBP
C) Automated susceptibility testing always underestimates aztreonam MICs (minimum inhibitory concentrations) for ESBL-producing organisms due to inoculum effects at low bacterial density
D) Aztreonam is hydrolyzed by all classes of beta-lactamases including ESBLs and is included in automated susceptibility panels only as a screening surrogate for third-generation cephalosporin resistance
E) Aztreonam is hydrolyzed by ESBL enzymes, and in vitro susceptibility at standard inocula may not predict clinical success because higher in vivo bacterial burdens (the inoculum effect) can produce sufficient ESBL to overwhelm aztreonam at achievable tissue concentrations
ANSWER: E
Rationale:
Aztreonam is hydrolyzed by ESBL enzymes (CTX-M [cefotaxime-Munich enzyme]-type ESBLs, TEM [Temoniera]-derived ESBLs, and SHV [sulhydryl-variable]-derived ESBLs). A critical limitation of in vitro susceptibility testing is the inoculum effect: automated susceptibility panels use standardized low bacterial inocula, and at these concentrations ESBL enzyme production may be insufficient to hydrolyze aztreonam before it reaches its target. However, in vivo infections involve far higher bacterial burdens, generating enough ESBL to hydrolyze aztreonam at achievable clinical concentrations. Clinical failures with aztreonam against ESBL-producing organisms have been documented despite in vitro susceptibility, and guidelines recommend against relying on aztreonam monotherapy for serious ESBL-E (ESBL-producing Enterobacteriaceae) infections.
Option A: Option A is incorrect; aztreonam's PBP3 binding affinity is not reduced by ESBL production — the problem is enzymatic hydrolysis of the drug, not target binding impairment.
Option B: Option B is incorrect; while efflux pumps contribute to resistance in gram-negatives, this is not the primary reason for avoiding aztreonam in ESBL producers, and efflux pump upregulation by ESBL production is not a recognized mechanism.
Option C: Option C is incorrect; while the inoculum effect is real, automated panels do not uniformly underestimate MICs — the issue is that a susceptible MIC at standard inoculum may not reflect clinical behavior at high bacterial density.
Option D: Option D is incorrect; aztreonam is a therapeutic agent in its own right and is not used solely as a surrogate marker.
11. A 49-year-old man is in the ICU with ventilator-associated pneumonia caused by a carbapenem-resistant Acinetobacter baumannii (CRAB) isolate that produces OXA-23 (a class D carbapenemase) and is resistant to ceftazidime-avibactam and meropenem-vaborbactam. The infectious disease team considers cefiderocol as salvage therapy. Which of the following best describes the mechanism by which cefiderocol achieves activity against carbapenem-resistant organisms that have lost outer membrane porins?
A) Cefiderocol binds to bacterial lipopolysaccharide on the outer membrane surface, triggering autolytic enzymes that disrupt the cell wall from outside the periplasm
B) Cefiderocol is conjugated to a catecholate siderophore moiety that hijacks the organism's iron-uptake transport system, allowing active translocation across the outer membrane through TonB-dependent transporters independent of standard porins
C) Cefiderocol is a prodrug activated by bacterial nitroreductases in the periplasm, releasing a reactive cephalosporin fragment that binds PBP3 only after crossing the outer membrane via passive diffusion
D) Cefiderocol competes with bacterial siderophores for ferric iron binding, starving the organism of iron and simultaneously blocking OmpF (outer membrane protein F) porins used for carbapenem entry
E) Cefiderocol's extended C-3 side chain allows direct intercalation into the lipid bilayer of the outer membrane, creating transient pores through which the drug and other antibiotics can enter the periplasm
ANSWER: B
Rationale:
Cefiderocol is a siderophore-conjugated cephalosporin — a novel class that exploits bacterial iron acquisition to achieve outer membrane penetration independent of the standard OprD or OmpF porins that carbapenems and other beta-lactams rely upon. The catecholate siderophore moiety attached to cefiderocol chelates ferric iron (Fe3+) and is recognized as a ferric-siderophore complex by TonB-dependent outer membrane transporters, which actively transport it across the outer membrane. This iron-piracy mechanism bypasses porin loss, which is a major mechanism of carbapenem resistance in Acinetobacter baumannii, Pseudomonas aeruginosa, and CRE. Once in the periplasm, cefiderocol binds PBP3 (penicillin-binding protein 3, the cell division transpeptidase) with high affinity and is highly stable to hydrolysis by all beta-lactamase classes including NDM and OXA-23.
Option A: Option A is incorrect; cefiderocol does not act on cell surface lipopolysaccharide and does not trigger autolytic enzymes from the outside.
Option C: Option C is incorrect; cefiderocol is not a prodrug and does not require nitroreductase activation; it is the intact molecule that binds PBP3.
Option D: Option D is incorrect; cefiderocol does not block OmpF porins or starve organisms of iron by competitive siderophore displacement; it uses iron binding as a delivery vehicle, not as a therapeutic mechanism.
Option E: Option E is incorrect; cefiderocol does not create lipid bilayer pores; its outer membrane penetration is via active TonB-dependent transport.
12. A clinical pharmacist is counseling a resident on the spectrum of meropenem-vaborbactam. The resident asks specifically about the activity of vaborbactam and why this combination fails against NDM-producing organisms despite being active against other carbapenem-resistant Enterobacteriaceae (CRE). Which of the following best explains the limitation of vaborbactam against NDM?
A) Vaborbactam is a beta-lactam inhibitor that forms a covalent bond with NDM's zinc cofactors, but the bond is too rapidly reversible to sustain enzyme inhibition at clinical drug concentrations
B) Vaborbactam inhibits NDM at high concentrations but clinical dosing of meropenem-vaborbactam does not achieve sufficient tissue concentrations to inhibit NDM in deep-seated infections
C) Vaborbactam is a boronic acid-based inhibitor of serine beta-lactamases (class A and class C); it does not inhibit class B metallo-beta-lactamases such as NDM because its mechanism requires covalent interaction with a serine residue that class B enzymes lack
D) Vaborbactam is hydrolyzed by NDM before it can accumulate in the periplasm, making it incapable of inhibiting NDM even transiently at any achievable dose
E) Meropenem-vaborbactam is active against NDM at standard dosing but requires prolonged extended infusion to maintain sufficient drug exposure for metallo-enzyme inhibition
ANSWER: C
Rationale:
Vaborbactam is a cyclic boronic acid inhibitor that works by forming a reversible covalent tetrahedral intermediate with the catalytic serine residue of class A (KPC, some CTX-M) and class C (AmpC) serine beta-lactamases. Like avibactam (a diazabicyclooctane inhibitor), vaborbactam's mechanism is fundamentally serine-dependent: it cannot interact productively with the zinc-containing active site of class B metallo-beta-lactamases, which have no catalytic serine. NDM, VIM, and IMP are class B metallo-beta-lactamases that use zinc ions to activate a hydroxide nucleophile for hydrolysis of the beta-lactam ring; vaborbactam has no mechanism of action against this zinc-based system. Therefore, meropenem-vaborbactam retains activity against KPC-CRE (where KPC is a class A serine carbapenemase) but fails against NDM-CRE.
Option A: Option A is incorrect; vaborbactam does not interact with NDM's zinc cofactors at all — rapid reversibility is not the issue; the inhibitor's mechanism is simply incompatible with the metallo-enzyme active site.
Option B: Option B is incorrect; the failure against NDM is mechanistic, not a matter of achievable tissue concentrations.
Option D: Option D is incorrect; vaborbactam is not a substrate for NDM hydrolysis; it simply has no inhibitory mechanism against a zinc-dependent enzyme.
Option E: Option E is incorrect; meropenem-vaborbactam does not have activity against NDM at any dosing regimen, extended infusion or otherwise.
13. A 74-year-old man on mechanical ventilation develops ventilator-associated pneumonia with an isolate identified as carbapenem-resistant Acinetobacter baumannii (CRAB) producing OXA-23. The isolate is resistant to imipenem, meropenem, ceftazidime-avibactam, and meropenem-vaborbactam. The infectious disease consultant recommends sulbactam-durlobactam (Xacduro). Which of the following best explains the mechanism by which this combination achieves activity against OXA-23-producing CRAB?
A) Sulbactam has intrinsic antibacterial activity against Acinetobacter through direct PBP1 and PBP3 binding; durlobactam is a DBO (diazabicyclooctane) inhibitor that protects sulbactam from hydrolysis by OXA-23 and other class D beta-lactamases expressed by CRAB
B) Durlobactam is a class B metallo-beta-lactamase inhibitor that chelates the zinc cofactors of OXA-23, while sulbactam acts as a carbapenem-sparing beta-lactam with intrinsic antipseudomonal activity
C) Sulbactam inhibits OXA-23 enzyme transcription by binding the OXA-23 gene promoter, while durlobactam provides direct anti-Acinetobacter bactericidal activity by binding PBP2 with high affinity
D) Durlobactam is a siderophore-conjugated inhibitor that delivers sulbactam across the outer membrane of CRAB via TonB-dependent transporters, bypassing porin loss resistance
E) Sulbactam-durlobactam is active against CRAB because durlobactam inhibits the MexAB-OprM efflux pump that exports sulbactam from the Acinetobacter periplasm before it can reach its PBP targets
ANSWER: A
Rationale:
Sulbactam possesses intrinsic antibacterial activity against Acinetobacter baumannii that distinguishes it from other beta-lactamase inhibitors (clavulanate, tazobactam, avibactam, vaborbactam) which have no direct antibacterial action. Sulbactam's Acinetobacter activity is mediated through direct binding to PBP1 and PBP3 of A. baumannii, inhibiting cell wall synthesis. However, CRAB strains producing OXA-23 and other class D carbapenemases readily hydrolyze sulbactam, rendering it ineffective as monotherapy. Durlobactam is a diazabicyclooctane (DBO) inhibitor — structurally related to avibactam and relebactam — that inhibits class A, class C, and class D serine beta-lactamases including OXA-23 and OXA-58, the dominant carbapenemases in CRAB. By protecting sulbactam from OXA hydrolysis, durlobactam restores sulbactam's intrinsic anti-Acinetobacter activity. This combination (sulbactam-durlobactam, marketed as Xacduro) is the first FDA-approved targeted therapy for CRAB infections.
Option B: Option B is incorrect; OXA-23 is a class D serine beta-lactamase, not a class B metallo-enzyme, so zinc chelation is irrelevant; sulbactam also has no antipseudomonal activity.
Option C: Option C is incorrect; sulbactam is a beta-lactamase inhibitor/PBP ligand, not a transcriptional inhibitor, and does not interact with gene promoters.
Option D: Option D is incorrect; durlobactam is not a siderophore conjugate; that mechanism belongs to cefiderocol.
Option E: Option E is incorrect; MexAB-OprM is a Pseudomonas aeruginosa efflux pump; Acinetobacter baumannii uses different efflux systems (AdeABC, AdeFGH), and sulbactam-durlobactam's mechanism does not center on efflux pump inhibition.
14. A pharmacology student is studying the rationale for combining imipenem with cilastatin. The student understands that DHP-I (dehydropeptidase I) is the enzyme targeted by cilastatin but is unsure about its anatomical location. Which of the following correctly identifies where DHP-I is predominantly expressed and why this location is pharmacologically significant for imipenem metabolism?
A) DHP-I is expressed on hepatic sinusoidal endothelial cells, where it hydrolyzes imipenem during first-pass metabolism; cilastatin inhibits this hepatic inactivation to ensure adequate systemic exposure
B) DHP-I is a cytoplasmic enzyme expressed in pulmonary alveolar macrophages; cilastatin is included to prevent imipenem inactivation in lung tissue, preserving drug concentrations for pulmonary infections
C) DHP-I is located on the luminal surface of intestinal enterocytes, where it degrades orally administered carbapenem prodrugs before absorption; cilastatin enables oral imipenem bioavailability by preventing gut-wall hydrolysis
D) DHP-I is a plasma metalloprotease circulating in the bloodstream; cilastatin inhibits this enzyme to prevent imipenem inactivation during systemic distribution before it reaches infected tissues
E) DHP-I is a zinc-dependent metalloprotease located on the brush border (luminal surface) of proximal renal tubular cells, where it hydrolyzes imipenem as it is filtered and secreted into the tubular lumen, generating nephrotoxic metabolites; cilastatin inhibits DHP-I at this site to preserve imipenem urinary concentrations and prevent tubular toxicity
ANSWER: E
Rationale:
Dehydropeptidase I (DHP-I) is a zinc-dependent metalloprotease anchored to the apical (brush border) membrane of proximal renal tubular epithelial cells. As imipenem is filtered at the glomerulus and secreted into the tubular lumen, it encounters high concentrations of DHP-I on the brush border surface. DHP-I cleaves the beta-lactam ring of imipenem, generating a ring-opened metabolite that is nephrotoxic to tubular cells and also pharmacologically inactive. Without DHP-I inhibition, urinary concentrations of intact imipenem are inadequate for urinary tract infections, and renal tubular injury occurs. Cilastatin is a specific competitive inhibitor of DHP-I; it has no antibacterial activity and no beta-lactamase inhibitory activity — its sole pharmacological purpose is to protect imipenem at the renal brush border. Meropenem and doripenem are not significantly hydrolyzed by DHP-I and do not require cilastatin.
Option A: Option A is incorrect; DHP-I is not a hepatic enzyme, and imipenem does not undergo significant hepatic first-pass metabolism.
Option B: Option B is incorrect; DHP-I is not expressed in pulmonary macrophages at clinically relevant levels; this is not the target of cilastatin.
Option C: Option C is incorrect; carbapenems have no oral bioavailability, and DHP-I is not a gut enterocyte enzyme limiting oral absorption.
Option D: Option D is incorrect; DHP-I is a membrane-bound enzyme, not a circulating plasma protease.
15. A 28-year-old woman with cystic fibrosis (CF) has chronic pulmonary colonization with Pseudomonas aeruginosa. Her pulmonologist discusses adding an inhaled antibiotic to her maintenance regimen. Aztreonam lysine for inhalation (AZLI) is considered. Which of the following best describes the pharmacological rationale for using an inhaled rather than intravenous formulation of aztreonam in this setting?
A) Inhaled aztreonam lysine is preferred because the lysine salt formulation is chemically modified to resist ESBL hydrolysis, whereas intravenous aztreonam is susceptible to the ESBLs produced by chronic Pseudomonas colonizers in CF airways
B) Inhaled aztreonam lysine is used because Pseudomonas aeruginosa in CF biofilms expresses PBP3 variants with reduced affinity for intravenous aztreonam; the inhaled route allows higher local concentrations that overcome these variant PBPs
C) Inhaled aztreonam lysine is reserved for patients with hypersensitivity to tobramycin because it is pharmacologically identical to intravenous aztreonam but has a modified lysine salt that reduces bronchospasm compared to the standard IV formulation
D) Inhaled aztreonam lysine achieves direct delivery to the airway surface liquid of the CF lung, providing high local bronchial concentrations against Pseudomonas aeruginosa while minimizing systemic exposure and adverse effects associated with repeated intravenous courses
E) Inhaled aztreonam lysine bypasses renal elimination entirely, making it suitable for CF patients with aminoglycoside-induced nephropathy who cannot tolerate drugs requiring renal dose adjustment
ANSWER: D
Rationale:
The rationale for inhaled aztreonam lysine (AZLI) in CF is primarily pharmacokinetic and safety-based. Chronic Pseudomonas aeruginosa airway colonization in CF requires long-term suppressive antibiotic therapy; repeated intravenous courses would expose patients to cumulative systemic toxicity and would require frequent venous access. Inhaled delivery deposits aztreonam directly onto the airway surface liquid at concentrations far exceeding those achievable systemically, ensuring adequate drug exposure at the site of infection (the airway biofilm) while maintaining very low systemic drug levels. This approach is analogous to the use of inhaled tobramycin and inhaled colistin in CF and reflects the broader principle that topical delivery to the target site optimizes the local pharmacodynamic profile while minimizing off-target exposure. AZLI is FDA-approved for improving respiratory symptoms in CF patients aged 7 years and older with Pseudomonas aeruginosa.
Option A: Option A is incorrect; the lysine salt formulation is chosen for pH compatibility with inhalation solutions, not for modified resistance to ESBL hydrolysis; chronic Pseudomonas colonization in CF does not typically involve ESBL production as the primary resistance mechanism.
Option B: Option B is incorrect; PBP3 variant affinity is not the reason for the inhaled route; the rationale is pharmacokinetic delivery optimization and systemic safety.
Option C: Option C is incorrect; inhaled aztreonam lysine is not pharmacologically identical to intravenous aztreonam in terms of formulation chemistry; the inhaled formulation is specifically buffered for airway delivery, and the indication is chronic Pseudomonas suppression in CF, not a second-line choice for tobramycin hypersensitivity specifically.
Option E: Option E is incorrect; renal elimination is a secondary consideration; the primary rationale is local airway delivery and minimization of systemic exposure.
16. An infectious disease pharmacist compares the three novel carbapenem-based combinations approved for CRE (carbapenem-resistant Enterobacteriaceae): ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam. A resident asks what distinguishes imipenem-relebactam from the other two in terms of its spectrum beyond KPC-CRE. Which of the following best characterizes a clinically important coverage advantage of imipenem-relebactam compared to meropenem-vaborbactam?
A) Imipenem-relebactam covers NDM-producing organisms because relebactam inhibits class B metallo-beta-lactamases through a zinc-chelating mechanism not shared by vaborbactam
B) Imipenem-relebactam has enhanced activity against multidrug-resistant Pseudomonas aeruginosa compared to meropenem-vaborbactam, because relebactam inhibits AmpC and OprD-independent resistance mechanisms active in difficult-to-treat Pseudomonas
C) Imipenem-relebactam covers OXA-48-type carbapenemases more reliably than meropenem-vaborbactam, because relebactam has broader class D inhibitory activity than vaborbactam
D) Imipenem-relebactam is preferred over meropenem-vaborbactam in CNS infections because relebactam achieves higher CSF concentrations than vaborbactam, supporting superior blood-brain barrier penetration
E) Imipenem-relebactam covers CRAB (carbapenem-resistant Acinetobacter baumannii) more reliably than meropenem-vaborbactam because relebactam has additional activity against the OXA-58 carbapenemase predominant in Acinetobacter
ANSWER: B
Rationale:
Relebactam is a diazabicyclooctane (DBO) inhibitor structurally related to avibactam, with inhibitory activity against class A (including KPC) and class C (AmpC) serine beta-lactamases. A clinically significant and distinguishing feature of imipenem-relebactam is its enhanced activity against multidrug-resistant Pseudomonas aeruginosa, including strains with carbapenem resistance mediated by AmpC overexpression, OprD porin loss, and some efflux pump upregulation. Relebactam's AmpC inhibitory activity, combined with imipenem's intrinsic anti-Pseudomonas spectrum, restores activity against Pseudomonas strains that have acquired carbapenem resistance through AmpC-based mechanisms. Meropenem-vaborbactam has less established activity against difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa). This makes imipenem-relebactam potentially useful for some MDR (multidrug-resistant) Pseudomonas infections in addition to KPC-CRE.
Option A: Option A is incorrect; relebactam does not inhibit class B metallo-beta-lactamases including NDM — this is a class effect of all current non-zinc chelating beta-lactamase inhibitors.
Option C: Option C is incorrect; relebactam's class D activity covers OXA-48 to some extent, but broader class D coverage over vaborbactam for OXA-48 is not the primary clinical distinguishing feature cited in guidelines.
Option D: Option D is incorrect; CSF penetration comparisons between relebactam and vaborbactam are not the basis for distinguishing these agents, and neither combination is established for CNS infections.
Option E: Option E is incorrect; relebactam does not have reliable activity against OXA-23- or OXA-58-producing CRAB, and this is not the coverage advantage that distinguishes imipenem-relebactam from meropenem-vaborbactam.
17. A clinical microbiology report identifies a Klebsiella pneumoniae isolate as carbapenem-resistant but notes that carbapenemase PCR (polymerase chain reaction) testing for KPC, NDM, VIM, IMP, and OXA-48 is negative. The infectious disease consultant explains that non-carbapenemase-mediated resistance is present. Which of the following combinations of mechanisms most accurately explains how Klebsiella pneumoniae achieves carbapenem resistance without producing a carbapenemase?
A) Upregulation of the KPC gene on a resident plasmid that is below the PCR detection threshold, combined with accelerated efflux of imipenem via the MexAB-OprM pump
B) Horizontal acquisition of a novel class B metallo-beta-lactamase gene not included in standard PCR panels, combined with simultaneous loss of OmpK35 porin
C) Loss or reduced expression of outer membrane porins (OmpK35, OmpK36) combined with upregulation of ESBL or AmpC beta-lactamases, reducing carbapenem entry while increasing enzymatic hydrolysis of any drug that enters the periplasm
D) Chromosomal mutation in the carbapenem binding site of PBP2 (penicillin-binding protein 2), producing a modified transpeptidase with dramatically reduced imipenem affinity similar to the PBP2a mechanism of MRSA
E) Upregulation of the outer membrane protein BamA, which sequesters carbapenems in the outer membrane leaflet before they can diffuse through porins to reach the periplasm
ANSWER: C
Rationale:
Non-carbapenemase-mediated carbapenem resistance in Enterobacteriaceae, particularly Klebsiella pneumoniae, is a clinically important phenotype distinct from carbapenemase-producing CRE. The mechanism involves two cooperating elements: loss or downregulation of outer membrane porins (specifically OmpK35 and OmpK36 in Klebsiella, or OmpF and OmpC in E. coli) combined with upregulation of ESBL (extended-spectrum beta-lactamase) or AmpC cephalosporinases. Porins are the primary channels through which carbapenems diffuse across the outer membrane into the periplasm. Porin loss alone reduces carbapenem entry but is insufficient to cause high-level resistance; however, when combined with increased ESBL or AmpC production, even the small amount of drug that enters is hydrolyzed before reaching PBP targets. This synergy produces intermediate or moderate-level carbapenem resistance without a carbapenemase. These strains are often negative on carbapenemase PCR panels, as seen in this case.
Option A: Option A is incorrect; MexAB-OprM is a Pseudomonas aeruginosa efflux system; Klebsiella uses different efflux pumps, and sub-threshold KPC would likely be detected by quantitative PCR.
Option B: Option B is incorrect; novel class B enzymes below PCR detection thresholds are theoretically possible but are not the established mechanism of non-carbapenemase CRE; porin loss plus ESBL/AmpC is the well-characterized non-carbapenemase pathway.
Option D: Option D is incorrect; PBP modification (analogous to MRSA's PBP2a) is not the established mechanism of carbapenem resistance in Enterobacteriaceae; this mechanism is characteristic of methicillin resistance in staphylococci.
Option E: Option E is incorrect; BamA is involved in outer membrane protein assembly, not carbapenem sequestration; this is not a recognized carbapenem resistance mechanism.
18. A 33-year-old man with a penicillin allergy presents with a polymicrobial intra-abdominal infection following bowel perforation. The surgical team proposes aztreonam monotherapy to avoid beta-lactam cross-reactivity concerns. An infectious disease consultant objects. Which of the following most accurately describes the coverage gap that makes aztreonam monotherapy inadequate for this clinical scenario?
A) Aztreonam covers aerobic gram-negative bacilli only; it has no activity against gram-positive organisms or anaerobes, leaving Enterococcus faecalis, Staphylococcus aureus, Bacteroides fragilis, and other anaerobes without coverage in a bowel perforation
B) Aztreonam has variable activity against anaerobes depending on oxygen tension in the abscess cavity; its anaerobic coverage is inadequate only in ischemic or necrotic tissue
C) Aztreonam lacks activity against Pseudomonas aeruginosa specifically, making it unsuitable for polymicrobial infections where Pseudomonas is a frequent contaminant of bowel flora
D) Aztreonam is rapidly inactivated by the reducing environment of peritoneal fluid, losing greater than 80% of its antibacterial activity before reaching the tissue concentrations required for bactericidal killing
E) Aztreonam lacks activity against ESBL-producing gram-negatives, which are the predominant pathogens in bowel perforation, making monotherapy microbiologically inadequate for the most likely organisms
ANSWER: A
Rationale:
Aztreonam is a monobactam with a spectrum restricted exclusively to aerobic gram-negative bacilli, including Enterobacteriaceae (E. coli, Klebsiella, Enterobacter) and Pseudomonas aeruginosa; it has no activity whatsoever against gram-positive cocci (Enterococcus, Staphylococcus, Streptococcus) or against anaerobes (Bacteroides fragilis, Peptostreptococcus, Fusobacterium). This narrow spectrum reflects aztreonam's high affinity for PBP3 of gram-negative organisms; it does not bind gram-positive PBPs because gram-positive organisms lack the outer membrane required for aztreonam to reach its target, and the PBP3 homologs in gram-positives have low aztreonam affinity. Intra-abdominal infections from bowel perforation are classically polymicrobial, involving aerobic gram-negatives (E. coli, Klebsiella), gram-positive enterococci, and obligate anaerobes (B. fragilis group). Aztreonam monotherapy leaves gram-positive and anaerobic coverage entirely absent. Standard therapy for bowel perforation requires coverage of all three groups, typically with a beta-lactam/beta-lactamase inhibitor, or a combination such as aztreonam plus metronidazole plus an agent covering gram-positives.
Option B: Option B is incorrect; aztreonam's lack of anaerobic coverage is absolute and structural, not dependent on oxygen tension; aztreonam simply has no activity against anaerobes under any conditions.
Option C: Option C is incorrect; aztreonam does have anti-Pseudomonas activity; the coverage gap is gram-positives and anaerobes, not Pseudomonas.
Option D: Option D is incorrect; aztreonam is not inactivated by peritoneal fluid; this is a fabricated pharmacokinetic mechanism.
Option E: Option E is incorrect; while ESBL-producing gram-negatives are a concern and aztreonam monotherapy is unreliable for ESBL producers, the primary gap in a bowel perforation is gram-positive and anaerobic coverage, not ESBL-related aztreonam susceptibility.
19. A 65-year-old man is admitted to the ICU with ventilator-associated pneumonia. The on-call resident reviews the antibiogram and notes that the patient's prior respiratory cultures grew Pseudomonas aeruginosa. The resident considers starting ertapenem as empiric therapy because the patient completed a course of ertapenem last month for a community-acquired intra-abdominal infection. The attending physician stops the resident. Which of the following best explains why ertapenem is inappropriate for empiric therapy in this patient?
A) Ertapenem is only approved for intravenous use and cannot be dosed with the extended infusion protocols required for adequate anti-Pseudomonas time above MIC in ventilator-associated pneumonia
B) Ertapenem does not penetrate epithelial lining fluid (ELF) in concentrations sufficient for gram-negative pneumonia therapy, making it pharmacokinetically inadequate for any pulmonary infection
C) Ertapenem requires co-administration with cilastatin, which is known to impair pulmonary surfactant function and is contraindicated in mechanically ventilated patients
D) Ertapenem causes QTc prolongation at therapeutic doses and is contraindicated in ICU patients receiving other QTc-prolonging medications
E) Ertapenem lacks reliable activity against Pseudomonas aeruginosa; because the patient has prior Pseudomonas colonization and is at high risk for Pseudomonas ventilator-associated pneumonia, empiric therapy must include an antipseudomonal carbapenem such as meropenem or imipenem
ANSWER: E
Rationale:
Ertapenem's most critical clinical limitation is its lack of activity against Pseudomonas aeruginosa (and Acinetobacter baumannii). This is not a trivial omission in the ICU setting: Pseudomonas aeruginosa is one of the most common pathogens in ventilator-associated pneumonia, and prior respiratory tract colonization is a strong predictor of subsequent Pseudomonas pneumonia. Using ertapenem in this setting would leave the most likely pathogen entirely untreated, risking clinical failure and selection of carbapenem-resistant strains. Antipseudomonal carbapenems — meropenem, imipenem-cilastatin, or doripenem — are required when Pseudomonas is a plausible pathogen. This restriction makes ertapenem appropriate for community-acquired and some healthcare-associated infections but categorically inappropriate for hospital-acquired or ventilator-associated pneumonia in a patient with Pseudomonas risk factors.
Option A: Option A is incorrect; ertapenem can be administered as an extended infusion, but its route of administration is not the reason it is avoided; the reason is lack of anti-Pseudomonas activity.
Option B: Option B is incorrect; ertapenem achieves adequate pulmonary tissue concentrations for susceptible pathogens; poor lung penetration is not the basis for avoiding it in this patient.
Option C: Option C is incorrect; ertapenem does not contain cilastatin — it does not require a DHP-I inhibitor because it is not substantially hydrolyzed by DHP-I.
Option D: Option D is incorrect; ertapenem is not associated with clinically significant QTc prolongation and does not carry a QTc-related contraindication.
20. An infectious disease fellow presents a case of CRE bacteremia to the attending. The isolate has been confirmed by PCR to produce NDM (New Delhi metallo-beta-lactamase). The fellow proposes ceftazidime-avibactam as definitive therapy. The attending explains why this choice is incorrect. Which of the following best explains why avibactam fails against NDM-producing organisms?
A) Avibactam is an effective inhibitor of NDM but is hydrolyzed by co-produced KPC enzymes in NDM-positive strains before it can reach the NDM active site in sufficient concentration
B) Avibactam inhibits NDM only at concentrations achievable with IV dosing in the renal pelvis; it fails in bacteremia because systemic avibactam concentrations are below the NDM Ki (inhibitor constant)
C) Avibactam forms an irreversible covalent bond with NDM's active site serine, but the inhibitor-enzyme complex dissociates too rapidly at physiological pH to maintain sustained NDM inhibition
D) NDM is a class B zinc-dependent metallo-beta-lactamase that hydrolyzes beta-lactams using a zinc-activated water molecule rather than a catalytic serine residue; avibactam's mechanism requires covalent carbamylation of a serine residue, making it pharmacologically incapable of inhibiting NDM
E) Avibactam is transported out of the periplasm of NDM-producing organisms by the AcrAB-TolC efflux pump before it can accumulate to inhibitory concentrations, a resistance mechanism that co-segregates with NDM plasmids
ANSWER: D
Rationale:
NDM (New Delhi metallo-beta-lactamase) is a class B metallo-beta-lactamase — an enzyme that uses two zinc ions to coordinate and activate a hydroxide nucleophile for direct hydrolytic attack on the carbonyl carbon of the beta-lactam ring. This is fundamentally different from class A, C, and D serine beta-lactamases, which use an active-site serine residue through a two-step acylation-deacylation mechanism. Avibactam is a diazabicyclooctane (DBO) inhibitor that exerts its effect by forming a reversible covalent carbamylation with the active-site serine of serine beta-lactamases; it has no interaction with zinc ions and cannot form a productive inhibitory complex with the metal-dependent NDM active site. This is not a matter of concentration or kinetics — avibactam literally has no mechanism of action against class B enzymes. The same principle applies to vaborbactam (a boronic acid serine-beta-lactamase inhibitor) and to all other currently approved serine-targeting beta-lactamase inhibitors.
Option A: Option A is incorrect; avibactam is not hydrolyzed by KPC; in fact, avibactam inhibits KPC. The issue with NDM is mechanistic incompatibility, not competitive inactivation by another enzyme.
Option B: Option B is incorrect; avibactam's failure against NDM is not a concentration-dependent issue; it is mechanistic — avibactam cannot inhibit a metallo-enzyme at any achievable concentration.
Option C: Option C is incorrect; avibactam forms a reversible (not irreversible) covalent bond with serine beta-lactamases, but it forms no bond at all with NDM, which lacks a catalytic serine.
Option E: Option E is incorrect; while AcrAB-TolC is a real efflux pump in Enterobacteriaceae, avibactam's failure against NDM is entirely mechanistic, not attributable to efflux.
21. A resident presents a case of carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia and proposes cefiderocol as first-line therapy. An attending physician acknowledges cefiderocol's activity against CRAB but raises a clinical concern arising from a specific trial. Which of the following most accurately describes the safety signal identified in the CREDIBLE-CR (Carbapenem-Resistant and Difficult-to-Treat Infections) trial that has influenced the use of cefiderocol in CRAB infections?
A) The CREDIBLE-CR trial demonstrated that cefiderocol caused significantly higher rates of Clostridioides difficile colitis in CRAB patients compared to best available therapy, leading to an FDA black-box warning against its use with concurrent antibiotics
B) The CREDIBLE-CR trial reported higher all-cause mortality in the cefiderocol arm compared to the best available therapy arm specifically in the Acinetobacter baumannii patient subset, raising questions about clinical efficacy in CRAB that remain under active investigation
C) The CREDIBLE-CR trial found that cefiderocol had significantly higher rates of nephrotoxicity than best available therapy in CRAB patients, requiring dose reduction in all patients with baseline renal impairment when used for Acinetobacter infections
D) The CREDIBLE-CR trial was terminated early for futility in the Acinetobacter subgroup after interim analysis demonstrated that cefiderocol MICs (minimum inhibitory concentrations) for CRAB exceeded clinically achievable plasma concentrations in all patients
E) The CREDIBLE-CR trial demonstrated that cefiderocol caused siderophore-mediated iron depletion in CRAB patients, producing a clinical iron-deficiency syndrome that required intravenous iron supplementation in the majority of treated patients
ANSWER: B
Rationale:
The CREDIBLE-CR trial (Bassetti et al., Lancet Infectious Diseases, 2021) was a non-randomized, open-label, pathogen-focused descriptive phase 3 trial comparing cefiderocol to best available therapy in patients with serious infections caused by carbapenem-resistant gram-negative bacteria. The trial confirmed cefiderocol's microbiological activity against a range of carbapenem-resistant pathogens. However, in the Acinetobacter baumannii patient subset — which used polymyxin-based best available therapy comparators — all-cause mortality was numerically higher in the cefiderocol arm than in the best available therapy arm. The mechanism of this mortality signal is not fully understood; hypotheses include the higher baseline severity of the cefiderocol-treated Acinetobacter patients and possible limitations of cefiderocol's bactericidal activity against CRAB in vivo despite in vitro susceptibility. This finding has not resulted in withdrawal but has introduced clinical caution about cefiderocol as first-line monotherapy for CRAB, and the signal is under ongoing investigation.
Option A: Option A is incorrect; no black-box warning for C. difficile colitis was issued for cefiderocol based on the CREDIBLE-CR trial; this adverse effect was not the identified signal.
Option C: Option C is incorrect; the CREDIBLE-CR safety signal concerned mortality, not nephrotoxicity; cefiderocol does not carry a prominent nephrotoxicity warning beyond standard beta-lactam monitoring.
Option D: Option D is incorrect; the trial was not terminated early for futility; it completed enrollment and reported results, with the mortality signal emerging from the completed dataset.
Option E: Option E is incorrect; cefiderocol uses bacterial siderophore pathways for uptake rather than depleting host iron; clinical iron-deficiency syndrome is not a recognized adverse effect of cefiderocol therapy.
22. A 58-year-old woman is in the ICU with CRE (carbapenem-resistant Enterobacteriaceae) bacteremia. She is hemodynamically unstable and the infectious disease team needs to initiate definitive therapy. Carbapenemase PCR testing was sent and results are pending. The attending states: "We cannot choose between ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam without the genotype result." Which of the following best explains why carbapenemase genotype is essential for selecting definitive therapy in CRE bacteremia?
A) Carbapenemase genotype determines the correct dose of any given beta-lactam/inhibitor combination; KPC-producing strains require double the standard dose of ceftazidime-avibactam compared to OXA-48-producing strains due to differences in enzyme affinity
B) Carbapenemase genotype is needed only to satisfy regulatory reporting requirements; the clinical treatment decision can be made on phenotypic susceptibility testing alone for all three available combinations
C) Each novel beta-lactam/inhibitor combination has a distinct carbapenemase inhibitory spectrum: ceftazidime-avibactam and meropenem-vaborbactam cover KPC but not NDM; aztreonam-avibactam covers NDM; OXA-48 is covered by ceftazidime-avibactam but not meropenem-vaborbactam; selecting the wrong agent for the carbapenemase present will result in predictable clinical failure
D) Carbapenemase genotype is required because KPC-producing strains are always susceptible to at least one available novel agent, while NDM-producing strains are universally resistant to all currently approved combinations and require compassionate use cefiderocol
E) Carbapenemase genotype testing is performed to identify co-produced resistance genes rather than to guide antibiotic selection; the genotype predicts which resistance genes may be transmitted to other organisms in the ICU rather than which drug will treat the current patient
ANSWER: C
Rationale:
The genotype-first approach to CRE therapy is essential because the three primary novel beta-lactam/inhibitor combinations have non-overlapping carbapenemase coverage profiles that directly determine clinical efficacy. KPC (class A serine carbapenemase) is inhibited by avibactam, vaborbactam, and relebactam; ceftazidime-avibactam and meropenem-vaborbactam are both effective for KPC-CRE. NDM (class B metallo-beta-lactamase) is not inhibited by avibactam or vaborbactam; the only approved combination with activity against NDM is aztreonam-avibactam (or aztreonam combined with ceftazidime-avibactam), which relies on aztreonam's intrinsic NDM stability plus avibactam's inhibition of co-produced serine beta-lactamases. OXA-48 (class D serine carbapenemase) is inhibited by avibactam but not reliably by vaborbactam; ceftazidime-avibactam covers OXA-48-CRE while meropenem-vaborbactam does not. Administering meropenem-vaborbactam to an NDM-CRE patient, or relying on ceftazidime-avibactam for a vaborbactam-only scenario, will result in predictable treatment failure in a bacteremic patient with high mortality risk. Genotypic confirmation — by PCR or whole-genome sequencing — is therefore the standard of care before finalizing definitive therapy.
Option A: Option A is incorrect; carbapenemase genotype does not alter dosing schedules for these agents; dosing adjustments are based on renal function, not enzyme subtype.
Option B: Option B is incorrect; phenotypic susceptibility testing has important limitations for these combinations — in vitro testing may not reliably predict clinical outcomes, and the genotype determines which agent will work mechanistically regardless of phenotypic MIC results.
Option D: Option D is incorrect; effective options for NDM-CRE do exist (aztreonam-avibactam, cefiderocol as salvage), so NDM is not universally resistant to all approved therapies.
Option E: Option E is incorrect; carbapenemase genotype is directly and primarily used for therapeutic decision-making, not solely for infection control surveillance purposes.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.